Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Many Patients 80 Years and Older with Advanced Non-small Cell Lung Cancer (NSCLC) Can Tolerate Chemotherapy

Many Patients 80 Years and Older with Advanced Non-small Cell Lung Cancer (NSCLC) Can Tolerate... ORIGINAL ARTICLE Many Patients 80 Years and Older with Advanced Non-small Cell Lung Cancer (NSCLC) Can Tolerate Chemotherapy Ozden Altundag, MD,* David J. Stewart, MD,* Frank V. Fossella, MD,* Gregory D. Ayers, MS,† Wei Wei, MS,† Xian Zhou, PhD,† and Ralph G. Zinner, MD* advanced NSCLC has been learned from studies of patients Abstract: People 80 years of age and older constitute 17.8% of all largely younger than 70 years old. lung cancer patients in the United States. Because the life expect- Platinum-based chemotherapy has been shown to both ancies of 80-year-old men and women are 87.3 years and 89.0 years, increase overall survival and improve the quality of life in respectively, non-small cell lung cancer shortens lives in addition to 3,4 patients with an adequate performance status (PS). A recent causing morbidity. In this retrospective study, all patients with study showed that bevacizumab improves survival when chemotherapy-naive advanced non-small cell lung cancer 80 years added to paclitaxel/carboplatin in patients with nonsquamous of age and older treated at the M. D. Anderson Cancer Center with NSCLC. Additionally, second-line agents such as docetaxel one or more follow-ups were identified from the database for the 6,7 and pemetrexed improve survival and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Many Patients 80 Years and Older with Advanced Non-small Cell Lung Cancer (NSCLC) Can Tolerate Chemotherapy

Journal of Thoracic Oncology , Volume 2 (2) – Feb 1, 2007

Loading next page...
 
/lp/wolters-kluwer-health/many-patients-80-years-and-older-with-advanced-non-small-cell-lung-g0fxZJznCd

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
/JTO.0b013e3180311792
pmid
17410030

Abstract

ORIGINAL ARTICLE Many Patients 80 Years and Older with Advanced Non-small Cell Lung Cancer (NSCLC) Can Tolerate Chemotherapy Ozden Altundag, MD,* David J. Stewart, MD,* Frank V. Fossella, MD,* Gregory D. Ayers, MS,† Wei Wei, MS,† Xian Zhou, PhD,† and Ralph G. Zinner, MD* advanced NSCLC has been learned from studies of patients Abstract: People 80 years of age and older constitute 17.8% of all largely younger than 70 years old. lung cancer patients in the United States. Because the life expect- Platinum-based chemotherapy has been shown to both ancies of 80-year-old men and women are 87.3 years and 89.0 years, increase overall survival and improve the quality of life in respectively, non-small cell lung cancer shortens lives in addition to 3,4 patients with an adequate performance status (PS). A recent causing morbidity. In this retrospective study, all patients with study showed that bevacizumab improves survival when chemotherapy-naive advanced non-small cell lung cancer 80 years added to paclitaxel/carboplatin in patients with nonsquamous of age and older treated at the M. D. Anderson Cancer Center with NSCLC. Additionally, second-line agents such as docetaxel one or more follow-ups were identified from the database for the 6,7 and pemetrexed improve survival and

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Feb 1, 2007

There are no references for this article.